Challenging Cases in CML: Treatment Failure in First-line Therapy

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: March 09, 2015
Expiration Date: March 09, 2016

Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

This interactive case presentation will provide an overview of managing a patient with chronic myeloid leukemia who becomes resistant to standard first-line therapy.

Target Audience

This activity is designed for hematologists, oncologists, and associated multidisciplinary clinical specialists who provide care to patients with CML.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Outline potential treatments that may be used in patients experiencing treatment failure, focusing on the efficacy and safety of each agent
  • Implement therapeutic strategies for patients who are experiencing treatment failure, utilizing the most appropriate approach for the individual patient with CML

Agenda

Treatment Failure in First-line Therapy − Elias Jabbour, MD

Instructions for Participation and Credit

This activity is eligible for credit through March 9, 2016. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Elias Jabbour, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Elias Jabbour received his medical degree from Saint Joseph’s School of Medicine. He completed his residency at Hotel Dieu de France University Hospital, and his fellowship in hematology-oncology at the Gustave Roussy Institute. Dr. Jabbour joined The University of Texas MD Anderson Cancer Center as a fellow in the Department of Hematology/Leukemia and Stem Cell Transplantation and is currently associate professor in the Leukemia Department.

Dr. Jabbour has taken an active role in the medical community, participating in numerous scientific meetings. He has authored or co-authored numerous publications and abstracts, and serves as a reviewer for many scientific journals. He is actively involved in research in both acute and chronic forms of leukemia, as well as in clinical trials that led to the approval of several drugs in chronic myeloid leukemia (CML) and myelodysplastic syndromes. Dr. Jabbour’s research on resistance to imatinib and mutations of the protein kinase domain were presented in several international meetings and published in peer-reviewed journals. He is also developing tailored therapies to CML.

Accreditation

CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-15-024-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Elias Jabbour has received grant support related to research activities and consultant fees from ARIAD Pharmaceuticals, Inc., Pfizer Inc., and Teva Pharmaceutical Industries Ltd., in addition to consultant fees from Bristol-Myers Squibb Company.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Jabbour has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Jabbour has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@managingcml.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from ARIAD Pharmaceuticals, Inc., Novartis, and Teva Pharmaceuticals.

©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.